Highlights Sage Therapeutics, Inc.

Equities

SAGE

US78667J1088

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
13.69 ^USD	+0.81%		+2.70%	-36.83%

Apr. 25	Truist Securities Cuts Sage Therapeutics' Price Target to $18 From $22, Hold Rating Maintained	MT
Apr. 25	Transcript : Sage Therapeutics, Inc., Q1 2024 Earnings Call, Apr 25, 2024

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Earnings Flash (SAGE) SAGE THERAPEUTICS Reports Q1 Revenue $7.9M, vs. Street Est of $5.2M	Apr. 25	MT
Sage Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 25	CI
Top Midday Decliners	Apr. 17	MT
Sector Update: Health Care Stocks Advance Premarket Wednesday	Apr. 17	MT
Sector Update: Health Care	Apr. 17	MT
Earnings Focus Lifts Exchange-Traded Funds, Equity Futures Pre-Bell Wednesday	Apr. 17	MT
Top Premarket Decliners	Apr. 17	MT
Sage Therapeutics' Phase 2 Study of Dalzanemdor Fails to Meet Primary Endpoint	Apr. 17	MT
Sage Therapeutics, Inc. Announces Topline Results from Phase 2 PRECEDENT Study of DalzanemDor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinson's Disease	Apr. 17	CI
Sage Therapeutics Q4 Net Loss Narrows, Net Product Revenue Declines	Feb. 14	MT
Sage Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 14	CI
Earnings Flash (SAGE) SAGE THERAPEUTICS Posts Q4 Revenue $78M, vs. Street Est of $61M	Feb. 14	MT
Sage Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 14	CI
Sage Therapeutics, Inc. Enters into Lease Agreement with 55 Cambridge Parkway, LLC	Jan. 24	CI
Biogen, Sage Therapeutics Say Oral Pill Zurzuvae for Postpartum Depression Now Available by Prescription in US	Dec. 14	MT
Sage Therapeutics, Inc. and Biogen Inc. Announces ZURZUVAE 50 mg (Two 25 mg Capsules Per Day) CIV	Dec. 14	CI
Sage Therapeutics Q3 Loss Widens; Revenue Rises	Nov. 07	MT
Biogen-Sage Therapeutics postpartum depression pill priced at $15,900	Nov. 07	RE
Sage Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 07	CI
Earnings Flash (SAGE) SAGE THERAPEUTICS Reports Q3 Revenue $2.7M, vs. Street Est of $3.2M	Nov. 07	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Sage Therapeutics, Inc.

Equities

SAGE

US78667J1088

Highlights

Filters